Lipid and Cholesterol Metabolism in Health and Disease: A Focus on the Cross-Talk between Peripheral Tissues and Central Nervous System

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Endocrinology and Metabolism Research".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 6907

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy
Interests: metabolic syndrome; NAFLD/MAFLD; cross-talk between peripheral and central metabolism of glucose and lipids; diabetic cardiomyophaty; natural antioxidants; nutraceuticals and pharmacotherapy; oxidative stress; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cholesterol plays a fundamental role in the human body, as it is an essential component of all cell membranes, the precursor of steroid hormones and bile acids—which are necessary for the intestinal absorption of cholesterol, fats and lipophilic vitamins. Moreover, at the central nervous system (CNS) level, cholesterol contributes to maintaining physiological brain function. Cholesterol can be obtained through diet and through endogenous synthesis. Its homeostasis depends on a complex equilibrium deriving by its ingestion, absorption, synthesis and excretion mediated by lipoprotein trafficking. In this view, the correct metabolism of lipids also contributes to ensure key physiological functions.

On the other hand, the alteration of cholesterol and lipid homeostasis represents a major risk for metabolic and cardiovascular disorders, whereas at the CNS level, its impairment appears to be involved in several neurological diseases, such as Alzheimer’s and Parkinson’s diseases, Niemann–Pick C disease and depression. Moreover, although cholesterol metabolism in peripheral tissues is independent from metabolism in the brain due to the blood–brain barrier, the crosstalk between central and peripheral lipid metabolism still remains an underestimated item in both physiological and pathological conditions.

Consequently, the main purpose of this Special Issue is to shed new knowledge on the possible connections between peripheral and central metabolism of lipid and cholesterol metabolism to identify possible novel targets aimed to develop a therapeutic strategy to counteract detrimental effects of their dysregulation in chronic diseases.

Potential topics include but are not limited to the following:

  1. Physiological role of cholesterol and lipids:
    • Structural role in membranes;
    • LDL and HDL trafficking;
    • Hormone synthesis (central and peripheral steroids);
    • Bile acids and vitamins.
  2. Cholesterol/lipid metabolism and cardiovascular system.
  3. Cholesterol/lipid metabolism in the brain.
  4. Role of altered cholesterol/lipid metabolism in the enhancement of cardiometabolic risk (i.e., metabolic syndrome, diabetes, cardiomyopathies, skeletal muscle impairment and heart failure).
  5. Cholesterol/lipid metabolism dysregulation in neurological diseases (i.e., behavioural diseases and cognitive function dysregulation).
  6. The crosstalk between peripheral and central cholesterol/lipid metabolism in health and diseases (i.e., role of free radicals, mediators of inflammation, oxysterols, free fatty acids and miRNAs).
  7. Novel therapeutic approaches in the treatment of altered cholesterol/lipid metabolism (conventional drugs, nutraceuticals and innovative drugs).

Dr. Micaela Gliozzi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2102 KiB  
Article
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
by Hidekatsu Yanai, Hisayuki Katsuyama and Mariko Hakoshima
Biomedicines 2022, 10(2), 401; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines10020401 - 08 Feb 2022
Cited by 8 | Viewed by 2081
Abstract
The modulation of peroxisome proliferator-activated receptors (PPARs), the superfamily of steroid–thyroid–retinoid nuclear receptors, is expected to induce an amazing crosstalk between energy-demanding organs. Here, we aimed to study the effects of the novel selective PPARα modulator, pemafibrate, on metabolic parameters in patients with [...] Read more.
The modulation of peroxisome proliferator-activated receptors (PPARs), the superfamily of steroid–thyroid–retinoid nuclear receptors, is expected to induce an amazing crosstalk between energy-demanding organs. Here, we aimed to study the effects of the novel selective PPARα modulator, pemafibrate, on metabolic parameters in patients with dyslipidemia. We retrospectively studied patients who had taken pemafibrate and compared metabolic parameters at baseline with the data at 3, 6 and 12 months after the start of pemafibrate. Serum triglyceride significantly decreased and high-density lipoprotein-cholesterol significantly increased at 3, 6 and 12 months after the start of pemafibrate. Serum aspartate aminotransferase levels significantly decreased at 3 and 6 after the start of pemafibrate as compared with baseline. Serum alanine aminotransferase and gamma-glutamyl transferase significantly decreased and albumin significantly increased after 3, 6 and 12 months. HbA1c levels significantly decreased after 3 months. Further, serum uric acid significantly decreased after 12 months. Such metabolic favorable changes due to pemafibrate were significantly correlated with changes in serum lipids. In conclusion, we observed a significant improvement of liver function, HbA1c and serum uric acid along with an amelioration of dyslipidemia after the start of pemafibrate. Full article
Show Figures

Figure 1

Other

Jump to: Research

11 pages, 1496 KiB  
Case Report
Successful Treatment of a Rare Cholesterol Homeostasis Disorder Due to CYP27A1 Gene Mutation with Chenodeoxycholic Acid Therapy
by Petar Brlek, Luka Bulić, David Glavaš Weinberger, Jelena Bošnjak, Tomislav Pavlović, Svetlana Tomić, Zdravka Krivdić Dupan, Igor Borić and Dragan Primorac
Biomedicines 2023, 11(5), 1430; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11051430 - 12 May 2023
Cited by 3 | Viewed by 1891
Abstract
Cerebrotendinous xanthomatosis (CTX) is a genetic disorder of the cholesterol metabolic pathway, most often associated with variants in the CYP27A1 gene. The dysregulation of cholesterol metabolism results in the accumulation of metabolites such as cholestanol, which has a predilection for neuronal tissue and [...] Read more.
Cerebrotendinous xanthomatosis (CTX) is a genetic disorder of the cholesterol metabolic pathway, most often associated with variants in the CYP27A1 gene. The dysregulation of cholesterol metabolism results in the accumulation of metabolites such as cholestanol, which has a predilection for neuronal tissue and tendons. The condition is treatable with chenodeoxycholic acid (CDCA), which halts the production of these metabolites. We present two adult brothers, without diagnosis, suffering from ataxia, general muscle weakness and cognitive deficits. Both brothers suffered from early onset cataracts, watery stools and thoracic kyphoscoliosis. Magnetic resonance imaging revealed hyperintense alterations in the central nervous system and intratendinous xanthomas in the Achilles tendons. A biochemical analysis showed elevated levels of cholestanol, lathosterol and 7-dehydrocholesterol. Their family history was negative for neurological and metabolic disorders. Genetic testing revealed a pathogenic CYP27A1 variant (c.1184+1G>A) in both brothers, confirming the diagnosis. The patients were started on CDCA therapy and have shown significant improvement at their follow-up examinations. Early diagnosis and treatment initiation in CTX patients is of great importance, as the significant reversal of disease progression can be achieved. For this reason, clinical genetic testing is necessary when it comes to patients with an onset of cataracts, chronic diarrhea, and neurological symptoms in early childhood. Full article
Show Figures

Figure 1

14 pages, 961 KiB  
Case Report
Does Childhood Obesity Trigger Neuroinflammation?
by Valeria Domenica Zingale, Simone D’Angiolini, Luigi Chiricosta, Valeria Calcaterra, Giorgio Giuseppe Orlando Selvaggio, Gianvincenzo Zuccotti, Francesca Destro, Gloria Pelizzo and Emanuela Mazzon
Biomedicines 2022, 10(8), 1953; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines10081953 - 11 Aug 2022
Cited by 7 | Viewed by 1883
Abstract
Childhood obesity is constantly increasing around the world, and it has become a major public health issue. Considerable evidence indicates that overweight and obesity are important risk factors for the development of comorbidities such as cognitive decline, neuroinflammation and neurodegenerative diseases. It is [...] Read more.
Childhood obesity is constantly increasing around the world, and it has become a major public health issue. Considerable evidence indicates that overweight and obesity are important risk factors for the development of comorbidities such as cognitive decline, neuroinflammation and neurodegenerative diseases. It is known that during obesity, adipose tissue undergoes immune, metabolic and functional changes which could induce a neuroinflammatory response of the central nervous system (CNS). In this context, to inspect if obesity can start to trigger the neuroinflammation from a pediatric age, we surgically collected and analyzed adipose tissue from the periumbilical area of three obese children (AT-OB) and two normal-weight children (AT-Ctrl). We considered the transcriptomic profile of our samples to detect alterations in different biological processes that might be also involved in the inflammatory and neuroinflammatory response. Our results show alterations of lipid and fatty acids metabolism in AT-OB compared to the AT-Ctrl. We also observed an onset of inflammatory response in AT-OB. Interestingly, among the genes involved in neuroinflammation, GRN and SMO were upregulated, while IFNGR1 and SNCA were downregulated. Our study highlights that obesity may trigger inflammation and neuroinflammation from a pediatric age. Full article
Show Figures

Figure 1

Back to TopTop